microPET imaging of glioma integrin αvβ3 expression using 64Cu-labeled tetrameric RGD peptide

Journal of Nuclear Medicine

Volumn 46, Issue 10, 2005, Pages 1707-1718

  Wu, Yun ^a   Zhang, Xianzhong ^a   Xiong, Zhengming ^a   Cheng, Zhen ^a   Fisher, Darrell R ^b   Liu, Shuang ^c   Gambhir, Sanjiv S ^a   Chen, Xiaoyuan ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^c PURDUE UNIVERSITY   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

64Cu; Integrin; Micro PET; Multimeric peptide; RGD peptide; Tumor angiogenesis

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACETIC ACID DERIVATIVE; ARGINYLGLYCYLASPARTIC ACID; COPPER 64; DIMER; ECHISTATIN; IODINE 125; MONOMER; TETRAMER; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; COPPER; DIAGNOSTIC AGENT; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; DRUG INHIBITION; DRUG STRUCTURE; FEMALE; GLIOMA; ISOTOPE LABELING; MOUSE; NONHUMAN; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOCHEMISTRY; URINARY EXCRETION; ANIMAL; ANIMAL DISEASE; ANTIBODY SPECIFICITY; CHEMISTRY; DIMERIZATION; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; NUDE MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; COPPER RADIOISOTOPES; DIMERIZATION; GLIOMA; INTEGRIN ALPHAVBETA3; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; OLIGOPEPTIDES; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 27944457471     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg. 1998;88:1-10.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
3. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol. 2004;31:635-644.
4. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15-18.
5. 3 for angiogenesis. Science. 1994;264:569-571.
6. Puduvali VK. Inhibition of angiogenesis as a therapeutic strategy against brain tumor. Cancer Treat Res. 2004;117:307-336.
7. v integrin. Science. 1995; 270:1500-1502.
8. 3 integrin "vitronectin receptor". Int J Biochem Cell Biol. 1997;29:721-725.
9. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
10. Hwang R, Varner JV. The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am. 2004;18:991-1006.
11. 5 integrin expression in glioma periphery. Neurosurgery. 2001;49:380-390.
12. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer. 2004;90:561-565.
13. 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003;4:123-131.
14. 3-targeted magnetic resonance imaging. Nat Med. 1998;4:623-626.
15. 3. Circulation. 2003;108:336-341.
16. 3 in brain tumor xenografts. Cancer Res. 2004;64:8009-8014.
17. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des. 2004;10:1439-1455.
18. 99mTc-Labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug Chem. 2001;12:624-629.
19. 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004;6:350-359.
20. 18F-labeled dimeric RGD peptide. Mol Imaging. 2004;3:96-104.
21. 3 integrin binding peptides in a nude mouse model. Cancer Res. 2002;62:6146-6151.
22. Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Brother Radiopharm. 2002;17:641-646.
23. Janssen M, Frielink C, Dijkgraaf I, et al. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother Radiopharm. 2004;19:399-404.
24. 123I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol. 2004;31:11-19.
25. 64Cu-labeled RGD peptide. Bioconjug Chem. 2004;15:41-49.
26. 18F-Labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31:179-189.
27. 3-integrin expression. J Nucl Med. 2004; 45:1776-1783.
28. 3-targeted imaging of lung cancer. Neoplasia. 2005;7:271-279.
29. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61-69.
30. Sgouros G. Dosimetry of internal emitters. J Nucl Med. 2005;46(suppl):18S-27S.
31. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673-687.
32. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokmetics. J Nucl Med. 2001;42:326-336.
33. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
34. van Hagen PM, Breeman WA, Bernard HF, et al. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer. 2000;90:186-198.
35. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000;27:661-670.
36. 111In-DTPA-conjugated peptides. Nucl Med Biol. 2001;28:761-768.
37. 3-octreotide (SMT487): a phase 1 clinical study-pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510-518.
38. International Commission on Radiological Protection. 1990 Recommendations of the International Commission on Radiological Protection: ICRP Publication 60. Ann ICRP. 1991;21:6-10.
39. 3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res. 1999;5:3608-3616.
40. 64Cu-TETA- octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42:213-221.